NBIX Stock Cash Flow Statements

Neurocrine Biosciences Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Capital Expenditure

Neurocrine Biosciences Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31

cash flows from operating activities:
net income	107,500,000	7,900,000	129,800,000	65,000,000	43,400,000	147,700,000	83,100,000	95,500,000	-76,600,000	89,000,000	68,500,000	-16,900,000	13,900,000	-7,300,000	22,500,000	42,300,000	32,100,000	347,900,000	-57,600,000	79,600,000	37,400,000	34,000,000	53,789,000	51,338,000	-102,115,000	18,078,000	50,764,000	-5,913,000	-41,818,000	6,894,000	-11,125,000	-59,985,000	-78,326,000	-44,659,000	-36,887,000	-40,280,000	-19,264,000	-29,315,000	-34,435,000	-23,987,000	-1,192,000	-19,444,000	-15,875,000	-13,381,000	-11,842,000	-10,642,000	-11,131,000	-12,242,000	-12,075,000	9,490,000	-3,078,000	-501,000	-886,000	1,331,000	31,382,000	1,976,000	2,882,000	2,487,000	3,333,000	-5,152,000	-8,636,000	-7,916,000	-8,177,000	-15,280,000	-19,665,000	-28,854,000	-17,711,000	-20,971,000	-21,077,000	-127,975,000	-27,240,000	-26,364,000	-25,720,000	-14,712,000	-39,143,000	-27,449,000	-25,901,000	-23,908,000	26,151,000	-5,604,000	-18,830,000	-20,615,000	-1,647,000	-11,131,000	-12,380,000	3,193,000	-9,834,000	-10,225,000	-13,390,000	-38,787,000	-20,234,000	-19,751,000	-15,764,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	52,800,000	52,800,000	41,500,000	43,100,000	44,500,000	38,100,000	47,800,000	68,500,000	39,900,000	43,500,000	43,100,000	49,500,000	37,000,000
charges associated with convertible senior notes			0	49,700,000	88,700,000
impairment charges associated with leased properties			0
depreciation	6,300,000	6,600,000	5,600,000	6,400,000	5,300,000	4,900,000	4,600,000	4,200,000	4,100,000	3,900,000	4,000,000	3,900,000	3,300,000	3,000,000	2,800,000	2,600,000	2,500,000	2,200,000	2,200,000	2,100,000	2,100,000																																																										2,544,000	2,505,000	2,442,000
accretion of discount on available-for-sale debt securities	-3,400,000	-4,600,000
amortization of intangible assets	1,000,000	1,000,000	900,000	900,000	900,000	800,000	900,000	900,000	900,000
changes in fair values of equity investments	6,700,000	30,600,000
deferred income taxes	-37,400,000	-13,700,000	-34,900,000	-41,300,000	-15,600,000	20,600,000	-4,200,000	-41,500,000	-31,600,000	13,500,000	9,000,000	-3,100,000	-300,000	-4,700,000	5,700,000	9,500,000	-6,200,000
non-cash lease expense
other	-7,400,000	7,900,000	300,000	200,000	3,400,000	12,300,000	-6,500,000	-4,300,000	-2,400,000	1,100,000	700,000	1,500,000	800,000	-3,300,000	2,100,000	3,000,000	2,600,000	2,000,000	1,000,000	300,000	400,000	-38,000	676,000	0	116,000
change in operating assets and liabilities:
accounts receivable	-79,700,000	-36,900,000	-12,900,000	-17,600,000	-11,300,000	-21,400,000	-30,400,000	4,200,000	-41,700,000	-46,500,000	-22,200,000	-15,500,000	-78,000,000	-21,700,000	-5,300,000	-10,700,000	9,300,000	-200,000	-8,500,000	300,000	-22,100,000	-11,257,000	-18,795,000	-23,393,000	-15,724,000	-2,143,000	-11,451,000	1,978,000	-13,497,000	-1,309,000	-23,744,000
inventory	2,100,000	-1,700,000	-3,300,000	-5,300,000	1,100,000															-800,000	-3,900,000	-6,490,000	1,220,000	599,000	-1,753,000	383,000	-636,000			-782,000	-114,000
accounts payable and accrued liabilities	15,500,000	12,400,000	39,400,000	-59,500,000	-18,600,000	-83,000,000	124,400,000	16,200,000	6,700,000	37,600,000	32,800,000	32,700,000	11,500,000	19,100,000	8,700,000	18,000,000	11,000,000	-1,200,000	33,200,000	11,100,000	-16,200,000	41,611,000	4,605,000	24,306,000	-16,567,000	8,646,000	11,304,000	12,143,000	-7,870,000	16,231,000	10,480,000	7,554,000	-6,927,000	3,520,000	-306,000	3,531,000	-2,347,000	5,884,000	2,284,000	2,219,000	-546,000	1,547,000	1,922,000	1,356,000	-1,127,000	-923,000	-554,000	1,496,000	-968,000	-541,000	1,189,000	794,000	-1,999,000	1,234,000	82,000	1,852,000	-3,019,000	167,000	1,434,000	845,000	-1,461,000	-943,000	-2,485,000	249,000	-897,000	-3,269,000	-201,000	1,946,000	-11,465,000	8,199,000	1,631,000	1,753,000	-1,717,000	199,000	-1,805,000	442,000	-4,551,000	3,251,000	375,000	-1,017,000	-6,504,000	-4,336,000	3,060,000	-18,467,000	-11,406,000
other assets and liabilities	23,000,000	2,500,000	-18,800,000	-3,900,000	-2,800,000	51,600,000	-50,900,000	71,400,000	-24,300,000	3,500,000	-18,500,000	8,500,000	-10,700,000	12,500,000	-27,200,000	3,800,000	1,700,000	6,100,000	-28,300,000
cash flows from operating activities	102,000,000	64,800,000	158,000,000	64,600,000	130,300,000	123,500,000	212,000,000	179,600,000	-125,200,000	143,000,000	98,800,000
cash flows from investing activities:
purchases of available-for-sale debt securities	-315,100,000	-273,200,000																					-231,189,000
sales and maturities of available-for-sale debt securities	298,600,000	298,100,000																					149,083,000
capital expenditures	-12,500,000	-10,700,000	-8,100,000	-11,600,000	-11,200,000	-5,400,000	-7,600,000	-6,800,000	-8,500,000	-1,800,000
free cash flows
cash flows from investing activities	-29,000,000	14,200,000	24,700,000	-28,200,000	-55,000,000	-201,800,000	-97,300,000	-125,900,000	-42,100,000	-115,600,000	-61,300,000
cash flows from financing activities:
issuances of common stock under benefit plans	14,400,000	32,100,000	26,400,000	15,800,000	69,900,000	35,400,000	18,800,000	2,900,000	8,200,000	24,600,000	11,400,000	2,600,000	6,100,000	1,800,000	7,500,000	3,000,000	15,200,000
repurchases of common stock	-17,700,000	-150,000,000
payments to settle convertible senior notes			0
cash flows from financing activities	-3,300,000	-117,900,000	26,400,000	-293,000,000	69,900,000	35,400,000	18,800,000	2,900,000	8,200,000	24,600,000	11,400,000
effect of exchange rate changes on cash and cash equivalents
change in cash, cash equivalents and restricted cash	69,900,000	-38,900,000	209,400,000	-256,600,000	145,200,000		133,500,000	56,600,000	-159,100,000		48,900,000	-106,900,000	-66,000,000		-56,900,000	15,400,000	165,500,000
cash, cash equivalents and restricted cash at beginning of period	0	241,000,000	0	0	259,100,000	0	0	0	270,700,000		0	0	344,000,000		0	0	190,300,000
cash, cash equivalents and restricted cash at end of period	69,900,000	202,100,000	209,400,000	-256,600,000	404,300,000	-42,600,000	133,500,000	56,600,000	111,600,000		48,900,000	-106,900,000	278,000,000		-56,900,000	15,400,000	355,800,000
supplemental disclosures:
accrued capital expenditures	-800,000	2,700,000
right-of-use assets acquired through operating leases			0				0							1,800,000	0	5,600,000	16,000,000
cash paid for interest			0			1,900,000	0			2,000,000	0			4,300,000	0			5,800,000	0			5,822,000	0
cash paid for income taxes	71,900,000	600,000	51,700,000	92,600,000	200,000	46,500,000	1,600,000	3,200,000	200,000	10,100,000	1,200,000			1,700,000	1,800,000			14,900,000				0	82,000
purchases of equity investments
accretion of discount on investments				-7,000,000	-7,100,000
changes in fair value of equity investments				19,900,000	-1,600,000
purchases of debt securities available-for-sale				-191,700,000	-320,100,000	-487,200,000	-362,700,000	-323,800,000	-206,200,000	-233,300,000	-134,200,000	-60,900,000	-192,800,000	-141,400,000	-275,600,000	-289,400,000	-93,700,000	-336,300,000	-110,600,000	-116,600,000	-172,000,000
sales and maturities of debt securities available-for-sale				175,100,000	276,300,000	290,800,000	273,000,000	204,700,000	203,900,000	162,200,000	71,200,000	101,100,000	176,500,000	174,000,000	159,700,000	202,900,000	161,300,000	193,100,000	136,200,000	214,700,000	206,500,000
purchases of equity securities										0	0	0	-7,700,000	0
non-cash capital expenditures				2,200,000	1,100,000	1,600,000	100,000	200,000	600,000	0	-200,000	-1,900,000	2,800,000	1,600,000	-1,900,000	2,100,000	100,000	300,000	200,000	100,000	800,000	898,000	-856,000
amortization of (discount) premium on investments
amortization of debt discount														4,100,000	4,200,000	4,000,000	3,900,000	4,800,000	5,200,000	5,000,000	5,000,000	4,865,000	4,774,000	4,685,000	4,598,000	4,512,000	4,428,000	4,347,000	4,265,000	4,182,000	4,104,000
amortization of debt issuance costs						100,000	200,000	200,000	200,000	200,000	200,000	400,000	400,000	300,000	200,000	300,000	300,000	400,000	300,000	400,000	300,000	353,000	349,000	346,000	341,000	337,000	334,000	329,000	326,000	322,000	319,000
changes in fair value of equity securities
loss on extinguishment of convertible senior notes										0	0
changes in operating assets and liabilities:
acquisition of business, net of cash acquired
repurchases of convertible senior notes
change in cash and cash equivalents and restricted cash																				228,100,000	74,700,000	-56,321,000	25,344,000	68,207,000	-68,936,000
supplemental disclosure:
right-of-use assets obtained in exchange for new operating lease liabilities
changes in fair value of equity security investments							40,100,000	-37,300,000	-2,200,000
inventories							2,900,000	1,600,000	1,800,000	3,900,000	-7,700,000	-300,000	1,500,000	-5,000,000	2,800,000	1,800,000	-2,100,000	-7,300,000
purchases of equity security investments							0	0	-31,300,000
repurchase of convertible senior notes											0
change in fair value of equity securities
cash and cash equivalents and restricted cash at beginning of period																				0	115,500,000	0	0
cash and cash equivalents and restricted cash at end of period																				228,100,000	190,200,000	-56,321,000	25,344,000
change in fair value of equity security investments											-11,100,000	7,400,000	-19,900,000		8,200,000	0	-700,000		7,000,000	-11,300,000	16,500,000
purchases of property and equipment												-8,800,000	-7,600,000	-8,900,000	-5,700,000	-4,300,000	-4,500,000	-4,500,000	-400,000	-4,700,000	-1,300,000	-2,812,000	-3,544,000	-4,453,000	-3,939,000	-6,010,000	-12,359,000	-4,643,000	-1,800,000	-2,377,000	-2,804,000	-397,000	-1,362,000	-347,000	-777,000	-2,243,000	-741,000	-828,000	-316,000	-510,000	-280,000	-439,000	-269,000	-649,000	-255,000	-191,000	-31,000	-264,000	-59,000	-42,000	-335,000	-190,000	-404,000	-40,000	-562,000	-128,000	-20,000	-12,000	-86,000			0	-10,000	-1,000	-24,000	-137,000	-30,000	-874,000	-281,000	-133,000	-318,000	-108,000	-65,000	-86,000	-282,000	-2,020,000	-722,000	-2,973,000	-1,670,000	-1,078,000	-1,514,000	-5,595,000	-7,120,000	-16,381,000	-24,051,000	-17,436,000	-10,899,000	-20,870,000	-1,234,000	-1,306,000	-1,525,000	-2,077,000	-392,000
reconciliation of net income to net cash from operating activities:
net cash from operating activities													-40,500,000	4,200,000	61,800,000	103,200,000	87,300,000	88,900,000	-17,500,000	118,900,000	38,200,000	102,553,000	97,826,000	64,166,000	-112,491,000	50,454,000	68,917,000	20,479,000	-38,486,000	40,575,000	-9,310,000	-48,239,000	-77,357,000	-31,625,000	-31,010,000	-14,335,000	-29,211,000	-15,203,000	-18,572,000	13,961,000	-18,183,000	-15,309,000	-12,099,000	-9,965,000	-9,767,000	-10,879,000	-10,780,000	-9,860,000	1,912,000	-8,909,000	-8,303,000	-6,878,000	-11,204,000	11,037,000	2,772,000	-5,910,000	-8,580,000	-17,303,000	10,241,000	69,193,000	-12,188,000	-13,973,000	-11,101,000	-13,631,000	-14,390,000	-16,299,000	-14,696,000	-15,011,000	-28,167,000	-4,226,000	-21,501,000	-18,754,000	-14,853,000	-16,799,000	-33,742,000	-28,443,000	-20,350,000	-22,904,000	45,597,000	-27,508,000	-25,979,000	-29,056,000	-6,885,000	-38,129,000	-25,918,000	-1,642,000	-6,375,000	-17,673,000	62,818,000	-32,787,000	-14,705,000	-19,780,000	-12,093,000
net cash from investing activities													-31,600,000	23,700,000	-126,200,000	-90,800,000	63,100,000	-147,700,000	25,200,000	93,400,000	33,200,000	-166,158,000	-85,646,000	-243,000	40,974,000	-106,256,000	-45,095,000	-34,514,000	-57,050,000	-59,281,000	-35,392,000	-212,843,000	56,646,000	15,068,000	43,196,000			22,052,000	-47,860,000	-53,912,000	-116,094,000	15,545,000	3,216,000	-58,396,000	-65,731,000	20,729,000	-1,305,000	20,993,000	-35,077,000	27,887,000	10,655,000	-28,087,000	-45,216,000	-468,000	17,861,000	193,000	-21,135,000	-6,075,000	-28,053,000	-26,300,000	5,724,000	6,086,000	7,802,000	581,000	-2,412,000	4,916,000	3,229,000	-320,000	36,603,000	-6,578,000	21,439,000	-7,519,000	13,494,000	23,165,000	24,749,000	12,927,000	59,440,000	-9,802,000	-22,716,000	31,456,000	10,444,000	6,129,000	57,674,000	9,067,000	-54,401,000	-31,112,000	-93,812,000	-18,588,000	-43,134,000	17,719,000	21,719,000	14,995,000	-100,454,000
partial repurchase of convertible senior notes														0	0	0	-100,000
net cash from financing activities													6,100,000	1,800,000	7,500,000	3,000,000	15,100,000	-179,400,000	2,500,000	15,800,000	3,300,000	7,284,000	13,164,000	4,284,000	2,581,000	1,782,000	5,490,000	6,123,000	16,135,000	5,600,000	3,022,000	506,493,000	1,531,000	63,000	1,329,000	936,000	62,000	968,000	740,000	1,759,000	273,525,000	1,732,000	484,000	274,000	136,241,000	50,000	2,661,000	1,625,000	966,000	288,000	118,000	43,000	83,253,000	22,000	45,000	162,000	57,000	99,000	22,000	3,000	21,359,000					-275,000	-325,000	-391,000	-461,000	60,118,000	-1,073,000	-699,000	-1,165,000	-1,145,000	-1,415,000	190,000	12,456,000	7,270,000	4,004,000	-19,000	-922,000	-740,000	11,170,000	13,788,000	12,474,000	14,788,000	189,111,000	2,746,000	4,414,000	2,755,000	1,756,000	1,327,000	-27,000
share-based compensation expense														35,600,000	37,100,000	28,600,000	32,900,000	21,000,000	26,700,000	29,500,000	22,800,000	21,317,000	20,250,000	17,931,000	15,764,000																																		875,000	843,000	559,000		1,699,000	1,041,000	1,870,000		1,751,000	2,247,000	2,189,000		2,554,000	2,794,000	2,409,000		3,188,000	2,690,000	6,788,000
issuance of common stock																			2,500,000	15,800,000	3,300,000	7,284,000	13,164,000	4,284,000	2,581,000	1,782,000	5,490,000	6,123,000	16,135,000	5,600,000	3,022,000	3,712,000	1,531,000	63,000	1,329,000	936,000	62,000	968,000	740,000	1,759,000	273,525,000	1,732,000	484,000	274,000	136,241,000	50,000	2,661,000	1,625,000	966,000	288,000	118,000	43,000	83,253,000	22,000	45,000	162,000	57,000	99,000	22,000	3,000	21,359,000					1,000	0			16,000	2,000	500,000	73,000	206,000	44,000	1,689,000	13,910,000	8,774,000	5,645,000	1,755,000	796,000	1,596,000	1,352,000	2,038,000	1,777,000	882,000	189,051,000	2,633,000	4,047,000	1,509,000	554,000	851,000	545,000
other current assets and liabilities																					-4,100,000
blank
net (accretion of discounts) amortization of premiums on investments																						-499,000
change in fair value of restricted equity securities																						7,182,000	28,450,000
other changes in operating assets and liabilities
purchases of marketable securities
sales and maturities of marketable securities
purchase of restricted equity securities																						-14,135,000	0
proceeds from sales of property and equipment																						0	4,000	0	4,000	4,000	0	12,000	18,000	0				0	0	10,000	3,000	0	0	0	9,000	0	0	5,000	40,000	2,000			13,000	7,000	0	0	25,000	58,000	86,000	18,000	83,000	94,000	35,000	61,000	146,000	239,000	609,000	33,000	312,000
proceeds from issuance of convertible senior notes
depreciation and amortization																							2,009,000	1,786,000	1,566,000	1,275,000	1,080,000	883,000	786,000	706,000	616,000	589,000	489,000	445,000	408,000	324,000	276,000	270,000	244,000	251,000	244,000	224,000	217,000	208,000	178,000	156,000	168,000	172,000	175,000	176,000	163,000	166,000	152,000	142,000	138,000	174,000	240,000	304,000	344,000	360,000	428,000	570,000	759,000	881,000	969,000	1,573,000	1,970,000	2,000,000	2,067,000	2,166,000	2,211,000	2,466,000	2,561,000	2,579,000	2,631,000	2,690,000	2,666,000					2,278,000	2,092,000	1,468,000	1,243,000
other current assets																							-2,198,000	2,128,000	-2,110,000		-3,943,000	-2,144,000	-750,000	568,000	-1,878,000				-281,000				-1,244,000
other liabilities																							3,331,000	5,947,000	5,363,000				-28,000																					0	1,000	27,000	-1,000	1,000				101,000	0	-1,481,000	45,000
amortization of discounts/premiums on investments																								-542,000	-290,000
change in fair value of investment in restricted equity securities																									-1,680,000
purchases of investments																									-116,307,000	-216,673,000	-105,213,000	-84,722,000	-139,354,000	-138,870,000	-79,506,000	-307,155,000	-57,877,000	-81,635,000	-47,653,000	-113,927,000	-55,561,000	-72,615,000	-89,577,000	-127,639,000	-159,221,000	-16,388,000	-32,819,000	-99,430,000	-108,907,000	-14,949,000	-34,767,000	-29,111,000	-66,501,000	-26,808,000	-16,344,000	-47,776,000	-75,385,000	-34,913,000	-28,307,000	-25,230,000	-50,649,000	-31,195,000	-31,870,000			-735,000	-719,000	-2,401,000	-12,945,000		-17,884,000
sales and maturities of investments																									215,936,000	116,423,000	72,477,000	54,839,000	84,086,000		46,911,000	94,239,000	116,085,000		91,626,000	100,396,000	126,754,000		42,009,000	74,221,000	43,398,000		36,304,000	41,678,000	43,391,000		33,487,000	50,349,000	31,470,000		27,334,000	19,907,000	30,548,000		46,668,000	25,533,000	29,453,000
investment in equity securities																									-54,720,000
cash and cash equivalents and restricted cash at beginning of the period																									147,191,000
cash and cash equivalents and restricted cash at end of the period																									78,255,000
amortization of premiums on investments																										13,000	372,000	552,000	512,000	554,000	606,000	327,000	269,000	369,000	711,000	1,043,000	1,397,000	1,721,000	1,732,000	1,568,000	1,011,000	1,047,000	1,151,000	977,000	617,000	735,000	750,000	719,000	639,000	655,000	990,000	867,000	623,000	569,000	619,000	652,000	501,000
deferred rent																												-44,000	-28,000	-28,000	1,470,000	-125,000	-114,000	-86,000	-72,000	-72,000	-64,000	-41,000	-28,000	80,000	-27,000	-5,000	7,000	6,000	6,000	27,000	39,000	38,000	38,000	67,000	79,000	79,000	80,000	102,000	117,000	116,000	99,000	161,000	173,000	173,000	173,000	200,000	-50,000	323,000	323,000
gain on sales of assets
cease-use expense																														0	0			0	0	0	-584,000													957,000				-7,000	-87,000	76,000	100,000	2,398,000	120,000	134,000	147,000	126,000	89,000	941,000	4,828,000
reimbursements for tenant improvements																										5,044,000
proceeds from issuance of senior convertible notes																														0	0
net change in cash, cash equivalents, and restricted cash
cash, cash equivalents, and restricted cash at beginning of the period
cash, cash equivalents, and restricted cash at end of the period
supplemental disclosures
non-cash share-based compensation expense																											13,070,000	11,851,000	19,879,000	13,452,000	10,204,000	9,890,000	8,976,000	7,953,000	6,319,000	7,274,000	6,918,000	6,226,000	13,903,000	4,663,000	3,600,000	2,444,000	2,664,000	2,827,000	2,447,000	1,696,000	1,711,000	1,680,000	1,732,000	1,310,000	1,370,000	1,373,000	1,426,000	907,000	904,000	395,000	712,000
other current liabilities																											0
net increase in cash, cash equivalents and restricted cash																											29,312,000
cash, cash equivalents and restricted cash at beginning of the period																											0	0	259,212,000
cash, cash equivalents and restricted cash at end of the period																											29,312,000	-7,912,000	179,811,000
gain on sale of assets																												-147,000	-201,000	-156,000	-188,000	-881,000	-879,000	-863,000	-844,000	-868,000	-856,000	-838,000	-828,000	-829,000	-839,000	-812,000	-806,000	-810,000	-794,000	-788,000	-787,000	-800,000	-795,000	-773,000	-759,000	-759,000	-783,000	-3,011,000	-86,000	718,000	-816,000	-2,958,000	-35,000	-53,000	-115,000	-2,894,000	-570,000	-21,000	-141,000			-164,000	-34,000
cease-use liability																													-62,000	-59,000	-60,000	-62,000	-66,000	-61,000	-58,000	-71,000	-110,000	-83,000	-175,000	-239,000	-113,000	-110,000	-104,000	-102,000	-102,000	-102,000	-97,000	-197,000	-194,000	-70,000	-64,000	-65,000	-64,000	-4,340,000	-729,000	-1,219,000	-1,214,000	-1,140,000	-1,129,000	-1,123,000	-1,145,000	-5,872,000	-977,000	-995,000	-2,007,000
net decrease in cash, cash equivalents and restricted cash																													-79,401,000
cash flow from operating activities
deferred revenues																																						0	0	0	10,231,000					-730,000	-729,000	-730,000	-730,000	-7,986,000	-7,990,000	-9,029,000	-9,237,000	-9,239,000	-9,238,000	-9,244,000	-9,306,000	75,828,000	-9,228,000	-3,364,000	-746,000	-717,000	-722,000	-731,000	-744,000	-719,000	-723,000	-730,000	-739,000	17,487,000	27,000	-27,000	36,000	-976,000	-477,000	-726,000	-4,358,000	-6,359,000	-5,448,000	-5,647,000	-5,683,000	-8,113,000	-7,163,000	-10,262,000	-12,695,000
cash flow from investing activities
sales/maturities of investments																																																										24,807,000	3,872,000	580,000	5,580,000	6,585,000	7,830,000	2,960,000	10,240,000		20,945,000
deposits and restricted cash																														113,000	0	470,000	-200,000	0	0	108,000	-200,000	0	24,000											-1,000	0			1,822,000	-24,000	0	-2,000	231,000	-4,000	-2,000	-2,000	-3,000	92,000	-10,000	5,000				6,000
cash flow from financing activities
net change in cash and cash equivalents
cash and cash equivalents at beginning of the year
cash and cash equivalents at end of the year
interest paid
taxes paid
other non-current liabilities																																			0				-25,000																								152,000	-1,489,000	-299,000	-827,000	-494,000	-181,000	-74,000	-393,000	97,000	382,000	-30,000	54,000	258,000	-1,641,000	1,286,000	487,000	450,000	283,000	163,000	356,000
net increase in cash and cash equivalents																															-41,680,000	245,411,000	-19,180,000		13,515,000	-29,055,000	41,106,000		-65,692,000	-38,192,000	139,248,000				60,743,000				-32,199,000				26,833,000	10,591,000	20,678,000	-5,555,000	-29,658,000	-23,279,000	-17,790,000	42,896,000	14,895,000				-16,802,000				7,975,000	49,314,000	-1,135,000	-26,972,000	-2,524,000	5,221,000	-10,408,000	-15,326,000	51,546,000	-25,436,000				-23,667,000			-67,845,000	-17,966,000			24,098,000			-3,458,000	-112,574,000
cash and cash equivalents at beginning of the period																															0	0	83,267,000		0	0	74,195,000		0	0	31,014,000		0	0	44,789,000		0	0	63,754,000		0	0	50,107,000		0	0	54,051,000		0	0	37,329,000		0	0	68,467,000		0	0	99,664,000		0	0	80,981,000		0	0	49,948,000		0	0	61,027,000		0	0	105,854,000		0	0	44,313,000		0	0	163,888,000
cash and cash equivalents at end of the period																															-41,680,000	245,411,000	64,087,000		13,515,000	-29,055,000	115,301,000		-65,692,000	-38,192,000	170,262,000		-8,399,000	-68,087,000	105,532,000		-9,424,000	12,758,000	31,555,000		2,470,000	-34,922,000	76,940,000		20,678,000	-5,555,000	24,393,000		-17,790,000	42,896,000	52,224,000		-3,299,000	-13,050,000	51,665,000		-11,792,000	-15,722,000	107,639,000		-1,135,000	-26,972,000	78,457,000		-10,408,000	-15,326,000	101,494,000		26,885,000	3,929,000	44,570,000		61,959,000	-15,274,000	38,009,000		88,924,000	-33,515,000	68,411,000		8,770,000	-3,458,000	51,314,000
supplemental cash flow information
cash paid for interest during the period
accounts receivable under collaboration agreements and other assets																																	-779,000				-14,577,000				-30,552,000
accounts receivable and other assets																																																					-515,000	21,122,000	-19,617,000	67,000	1,241,000
net cash provided by/ (used in) investing activities																																					70,255,000
receivables under collaboration agreements and other assets																																											-1,275,000	-1,046,000	850,000		-150,000	4,000	14,090,000		-339,000
net decrease in cash and cash equivalents																																											-8,399,000				-9,424,000				2,470,000												-3,299,000				-11,792,000													3,929,000	-16,457,000
loss on sale of investments																																																										0	0						320,000
realized gain on sale of auction rate securities																																																										-694,000	-35,000	-36,000	-555,000
fair value adjustment for auction rate security rights																																																														150,000	258,000	196,000	211,000
fair value adjustment of auction rate securities
other-than-temporary impairment for auction rate securities
interest paid on debt obligations
realized loss on sale of investments
deferred gain on sale of real estate																																																							-736,000				-716,000	-714,000	-715,000		-695,000	-694,000	-695,000
principal payments on debt																																																																		-276,000	-325,000	-424,000	-461,000	-48,643,000	-1,075,000			-1,351,000	-1,459,000	-1,499,000	-1,454,000					-61,656,000	-1,186,000
supplemental disclosures of cash flow information:
fair value adjustment for trading auction rate security rights
fair value adjustment trading for auction rate securities
amortization of premiums on short term-investments																																																											253,000						-10,000
proceeds from sale of trading securities																																																											9,100,000
accounts receivable and other current assets																																																											-4,248,000	-298,000	-167,000		-55,000	-188,000	121,000	911,000	-133,000	730,000	1,105,000	-216,000	-49,000	224,000	7,532,000	-6,052,000	1,306,000	3,925,000	-3,991,000	548,000	21,467,000	-18,130,000	2,559,000	-375,000	-2,194,000	-200,000	8,724,000
other assets
upfront licensing fees																																																											10,000,000
fair value adjustment for auction rate securities																																																															-330,000	-425,000	1,237,000
loss/(gain) on sale of investments
asset impairment
loan forgiveness on notes receivable																																																																														69,000	0			70,000	78,000
non-cash stock compensation expense
leaseback financing obligation
amortization of premiums/discounts on short term-investments																																																															0
other non-current assets																																																															-6,000	1,810,000	189,000	-172,000	14,000	112,000	-139,000	-22,000	-606,000	18,000	76,000	413,000	-176,000	-184,000	-529,000	-199,000	-49,000	-53,000	-335,000			287,000	300,000
gain on sale of investments
(gain)/loss on sale/abandonment of assets
(gain)/loss on sale of investments
purchases of short-term investments																																																																					-9,984,000	-44,172,000	-1,819,000	-9,651,000	-38,996,000	-1,523,000	317,000	-1,817,000	-61,021,000	-333,307,000	-29,552,000	580,000	-20,550,000	-7,210,000	-64,706,000	-182,368,000	-289,438,000	-85,855,000	-148,688,000	-101,071,000	-112,680,000	-69,731,000	-100,449,000	-49,843,000	-181,566,000
sales/maturities of short-term investments																																																																					46,688,000	38,885,000	23,450,000	2,240,000	52,555,000	24,249,000	24,714,000	16,764,000	121,183,000	326,478,000	8,506,000	31,954,000	33,033,000	5,940,000	130,050,000	207,959,000	301,100,000	57,582,000	65,775,000	103,853,000	73,280,000	88,756,000	123,693,000	66,915,000	81,504,000
gain on sale and disposal of assets
realized loss on auction rate securities
restricted cash																																																																			127,000
sale of property and equipment																																																																			71,000	276,000	174,000
non-cash compensation expense
payments received on notes receivable from employees
(gain)/loss on disposal of fixed assets
loan forgiveness on notes receivable from stockholder																																																																											0
proceeds from the sale of property and equipment
sales force allowance prepayment																																																																													8,240,000
principal payments on long-term obligations																																																																									-1,238,000								-1,718,000				-1,004,000		-14,840,000	-721,000	-646,000	-573,000	-592,000	-576,000	-572,000
loss on sale/abandonment of assets
deferred expenses																																																																																		997,000	-137,000	-24,000	164,000
purchase of prepaid royalty stream
proceeds received from debt
tax benefit from exercise of stock options
stock issued for prepaid royalty
loss on disposal of fixed assets
operating activities
investing activities
financing activities
gain on sale/abandonment of assets
proceeds from sale of property and building
non-cash compensation expenses																																																																															107,000	105,000	209,000		134,000	148,000	132,000
purchase of royalty stream																																																																																			0	0	-50,000,000
deposit and restricted cash																																																																															0	0	-525,000
proceeds from debt financing																																																																																					11,701,000
principal payments on long-term debt																																																																															-1,641,000
supplemental information:
increase in stockholder’s equity and prepaid royalties from issuance of common stock
as reported
stock option expense
pro forma net income
payments received on notes receivable from stockholders																																																																																										0
restricted cash and other non-current assets
deposits																																																																																			-550,000				0
proceeds received from issuance of debt
increase in property and related debt resulting from increasing ownership percentage in science park center llc
net income:
loss per share as reported
pro forma loss per share
deposit																																																																																					7,988,000				-2,500,000
(gain) loss on sale/abandonment of assets
proceeds from issuance of long-term debt
proceeds from capital lease financing																																																																																								834,000	1,013,000		1,690,000
increase in property and related debt resulting form increasing ownership percentage in science park center llc
adjustments to reconcile net income to net cash
used in operating activities:
loss on abandonment of assets
loan forgiveness on notes receivable from stockholders
proceeds received from long-term obligations

We provide you with 20 years of cash flow statements for Neurocrine Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Neurocrine Biosciences stock. Explore the full financial landscape of Neurocrine Biosciences stock with our expertly curated income statements.

The information provided in this report about Neurocrine Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.